Epigenetix is a clinical stage pharma company with a first-in-class oral cancer drug about to begin phase on trials at 5 leading US cancer centers. We will include patients with prostate cancer,  pancreatic cancer, breast cancer, sarcoma, NUT carcinoma and other cancers where our drug has shown
unprecedented anti-cancer activity. Our drug was selected among many
other drug candidates to potently inhibit three different validated
cancer drug targets:  p300/CBP + BRD4+ CECR2. Treatment
results in elimination of both the tumor itself as well as associated metastases. This powerful drug fights cancer in multiple ways: (1) by eradicating tumor cells directly (cytotoxic therapy), (2) by unleashing the body’s immune system (immunotherapy), and (3) by inhibiting cancer-inducing male and female hormone actions (hormone therapy). While presently pursued as monotherapy, synergy with checkpoint inhibitors, PARP inhibitors, CDK4/6 inhibitors as well as epigenetic drugs, such as EZH2 inhibitors ,has been shown preclinically.

Epigenetix

Joseph Collard

This department oversees the strategic direction and management of the organization.

Epigenetix

Org chart

Teams

Executive Leadership

Offices

Epigenetix

Org chart

Teams

Executive Leadership

Offices

Related companies